Almost 20 million people around the world are living with sickle cell anemia, where roughly 60000 newborns are born with β-Thalassemia annually. The existing treatment for patients of these diseases majorly focuses on blood transfusion or bone marrow transplant at predetermined intervals. However, none of these are safe due to the high risk of graft